, a CDMO, has appointed Ian Muir to the newly created position of commercial managing director, effective on February 24. Muir’s responsibilities will cross all three of the company’s service offerings in API manufacturing, formulation development, and formulated products. He will also lead the expansion of the business into new markets, including China and Japan. Muir will report directly to Robert Hardy, CEO, and will be joining the Aesica Board.
Previously, Muir worked at Catalent where he was responsible for the global provision of contract development and manufacturing services for oral dose forms. He also has commercial experience in contract manufacturing roles for pharmaceutical companies located in Europe, the US, and Australia.